First dementia treatment drug approved for Australia, supported by NIF capacity

Donanemab, developed by Lilly, is the first disease-modifying treatment for early-stage Alzheimer’s disease to be approved for use in Australia. The National Imaging Facility supported its developme

16 June 2025

New molecular-imaging network launched to benefit cancer, dementia imaging and new radiopharmaceuticals

A new national-scale molecular-imaging network that aims to improve cancer imaging, dementia diagnosis and treatment, and new radiopharmaceuticals was launched Saturday at the annual meeting for Austr

26 May 2025

National Imaging Facility granted $28m NCRIS funding to strengthen Australia’s advanced imaging network and bolster health research

The Commonwealth Government Department of Education has today announced National Imaging Facility (NIF) will receive $28m under the National Collaborative Research Infrastructure Strategy (NCRIS), to

19 October 2023

ABC News: New class of Alzheimer’s drugs showing promise in patients in early stage of disease

18 July 2023